scispace - formally typeset
Open AccessJournal ArticleDOI

Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

TLDR
An expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.
About
This article is published in Kidney International.The article was published on 2019-05-01 and is currently open access. It has received 350 citations till now. The article focuses on the topics: Kidney disease & Guideline.

read more

Citations
More filters
Journal ArticleDOI

Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients

TL;DR: Results from clinical studies of a number of HIF prolyl hydroxylase inhibitors are increasingly available and provide support for the continued evaluation of the risk-benefit ratio of this novel therapeutic approach to the treatment of anemia in CKD.
Journal ArticleDOI

Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.

TL;DR: Among patients undergoing hemodialysis, a high‐dose intravenous iron regimen administered proactively was superior to a low‐dose regimen administered reactively and resulted in lower doses of erythropoiesis‐stimulating agent being administered.
Journal ArticleDOI

Overview of iron metabolism in health and disease

TL;DR: An overview of the essential role of iron in biology, the regulation of systemic and cellular iron homeostasis, how imbalances in ironHomeostasis contribute to disease, and the implications for chronic kidney disease patients is provided.
Journal ArticleDOI

Iron deficiency anaemia revisited

TL;DR: This review provides recent updates and guidance on the diagnosis and management of iron deficiency anaemia in multiple clinical settings.
References
More filters
Journal ArticleDOI

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

TL;DR: Authors/Task Force Members: Piotr Ponikowski* (Chairperson) (Poland), Adriaan A. Voors* (Co-Chair person) (The Netherlands), Stefan D. Anker (Germany), Héctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK)
Journal ArticleDOI

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

TL;DR: Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
Journal ArticleDOI

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

TL;DR: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.
Related Papers (5)